Supernus Announces Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million...
Supernus to Participate in the Jefferies London Healthcare Conference
07 nov. 2023 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
02 nov. 2023 07h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
25 oct. 2023 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
16 oct. 2023 17h34 HE
|
Supernus Pharmaceuticals, Inc.
Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
09 oct. 2023 16h45 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
27 sept. 2023 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
09 sept. 2023 20h00 HE
|
Supernus Pharmaceuticals, Inc.
Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with...
Supernus to Participate in the Wells Fargo Healthcare Conference
31 août 2023 17h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Bethany L. Sensenig Joins Supernus’ Board of Directors
21 août 2023 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...